Gilead Sciences (NASDAQ:GILD) Price Target Lowered to $75.00 at UBS Group

Gilead Sciences (NASDAQ:GILD) had its price objective reduced by research analysts at UBS Group from $81.00 to $75.00 in a research report issued on Wednesday, Benzinga reports. The firm currently has a “neutral” rating on the biopharmaceutical company’s stock. UBS Group’s price target would suggest a potential upside of 13.36% from the company’s current price.

Several other analysts have also commented on GILD. Mizuho reduced their price target on shares of Gilead Sciences from $101.00 to $90.00 and set a “buy” rating on the stock in a research report on Thursday, February 22nd. Royal Bank of Canada reduced their price target on shares of Gilead Sciences from $76.00 to $75.00 and set a “sector perform” rating on the stock in a research report on Wednesday, February 14th. StockNews.com raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, March 26th. Cantor Fitzgerald reduced their price target on shares of Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 7th. Finally, Truist Financial lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating and reduced their price target for the company from $91.00 to $82.00 in a research report on Thursday, February 22nd. One analyst has rated the stock with a sell rating, nine have issued a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $84.71.

Gilead Sciences Trading Down 1.2 %

GILD stock opened at $66.16 on Wednesday. The company has a current ratio of 1.43, a quick ratio of 1.27 and a debt-to-equity ratio of 1.08. Gilead Sciences has a 12-month low of $65.90 and a 12-month high of $87.86. The stock has a market cap of $82.37 billion, a price-to-earnings ratio of 14.70, a PEG ratio of 0.92 and a beta of 0.19. The business’s 50-day moving average is $72.10 and its 200 day moving average is $76.58.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share for the quarter, missing the consensus estimate of $1.76 by ($0.04). The company had revenue of $7.12 billion for the quarter, compared to analyst estimates of $7.10 billion. Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The company’s revenue for the quarter was down 3.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.67 earnings per share. On average, sell-side analysts anticipate that Gilead Sciences will post 6.55 EPS for the current fiscal year.

Insider Buying and Selling at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $73.18, for a total transaction of $146,360.00. Following the sale, the insider now owns 100,936 shares of the company’s stock, valued at approximately $7,386,496.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 0.16% of the stock is owned by company insiders.

Institutional Investors Weigh In On Gilead Sciences

A number of large investors have recently made changes to their positions in the company. PCA Investment Advisory Services Inc. bought a new position in Gilead Sciences in the second quarter valued at approximately $25,000. Tompkins Financial Corp lifted its position in Gilead Sciences by 223.1% during the third quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 241 shares during the period. Private Wealth Management Group LLC bought a new stake in Gilead Sciences during the fourth quarter worth about $29,000. OFI Invest Asset Management bought a new position in shares of Gilead Sciences in the third quarter worth about $26,000. Finally, Fortitude Family Office LLC bought a new position in shares of Gilead Sciences in the fourth quarter worth about $29,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.